Dimerix Limited (ASX: DXB)
Health Care · Biotechnology · AU
AU$0.22
-2.22% today · -60.0% 1Y
Dimerix Limited (ASX: DXB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $92.18M and employs 15 people.
Over the last twelve months the share price has lost 60.0%, trading between 0.16 and 0.67.
Tweenvest scores Dimerix Limited across four factors: quality 31/100, value 40/100. Its strongest factor is value.
DXB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $92.18M
- Revenue (TTM)
- $4.40M
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- 0.35
- 52-week high
- AU$0.67
- 52-week low
- AU$0.16
- Avg volume (3M)
- —
- Shares outstanding
- 600.40M
- Employees
- 15
- Next earnings
- —
About Dimerix Limited
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.
- ISIN
- AU000000DXB7
- Listed since
- Jul 31, 1989
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| SynAct Pharma ABOM: SYNACT | $94.64M | Skr17.20 | +1.78% |
| Atara Biotherapeutics, Inc.NasdaqGS: ATRA | $94.15M | $9.36 | -0.27% |
| Medivir AB (publ)OM: MVIR | $93.71M | Skr1.51 | +0.80% |
| Cellectis S.A.ENXTPA: ALCLS | $92.50M | €1.14 | +0.98% |
| Rallybio CorporationNasdaqCM: RLYB | $90.38M | $16.93 | -0.53% |
| Equillium, Inc.NasdaqCM: EQ | $89.41M | $1.34 | -5.32% |
| ViGenCell Inc.KOSDAQ: A308080 | $89.05M | ₩5,840.00 | +0.52% |
| ImmuCell CorporationNasdaqCM: ICCC | $89.01M | $10.51 | +7.24% |
Figures last refreshed Oct 11, 2026.